Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 1127 matching drugs for RET — including drugs targeting any of its 233 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RET Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RET Direct 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RET Direct 3
pembrolizumab, belzutifan, lenvatinib RET Direct 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RET Direct 2
cabozantinib RET Direct 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib RET Direct 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib RET Direct 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a RET Direct 2
lenvatinib, pembrolizumab RET Direct 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate RET Direct 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a RET Direct 2
pembrolizumab, lenvatinib RET Direct 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu RET Direct 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin RET Direct 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery RET Direct 2
regorafenib RET Direct yes 2
regorafenib, laboratory biomarker analysis RET Direct 2
sorafenib, administered orally, ct/mri RET Direct 2
atezolizumab, cabozantinib RET Direct 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging RET Direct 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography RET Direct 1
cabozantinib, durvalumab, tremelimumab RET Direct 1
cabozantinib, nivolumab RET Direct 1
cabozantinib, pembrolizumab RET Direct 1
cisplatin, pemetrexed disodium, sorafenib RET Direct 1
erdafitinib RET Direct 1
everolimus, sorafenib RET Direct 1
gemcitabine, erlotinib, sorafenib RET Direct 1
gemcitabine, oxaliplatin, imatinib RET Direct 1
gemcitabine, placebo, sorafenib RET Direct 1
gemcitabine, sorafenib, radiotherapy RET Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff RET Direct 1
h101, tislelizumab, lenvatinib RET Direct 1
imatinib, irinotecan, carboplatin RET Direct 1
ko-2806, cabozantinib, adagrasib RET Direct 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil RET Direct 1
lenvatinib, bevacizumab RET Direct 1
nivolumab, cabozantinib RET Direct 1
oxaliplatin, sorafenib RET Direct 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) RET Direct 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel RET Direct 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel RET Direct 1
ponatinib RET Direct 1
radiation therapy, temozolomide, sorafenib RET Direct 1
regorafenib, lomustine RET Direct 1
regorafenib, nivolumab, capeox, folfox regimen RET Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil RET Direct 1
regorafenib, temozolomide RET Direct 1
selpercatinib RET Direct yes 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome RET Direct 1
sirolimus, vandetanib RET Direct 1
sorafenib RET Direct yes 1
sorafenib, erlotinb RET Direct 1
sorafenib, rad001 RET Direct 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide RET Direct 1
tace, lenvatinib, combined with tislelizumab group RET Direct 1
tace, tislelizumab, lenvatinib RET Direct 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 RET Direct 1
topotecan, sorafenib RET Direct 1
trc 105, sorafenib RET Direct 1
vandetanib RET Direct yes 1
vandetanib, 5 fluorouracil (fu), carboplatin, paclitaxel, external beam radiation therapy (rt) RET Direct 1
vandetanib, adjuvant therapy RET Direct 1
vemurafenib, sorafenib RET Direct 1
alectinib RET Direct yes 0
alectinib hydrochloride RET Direct yes 0
sorafenib tosylate RET Direct yes 0
sunitinib RET Direct yes 0
sunitinib malate RET Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
binimetinib and encorafenib BRAF SSL via BRAF yes 1
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
sunitinib KDR SSL via KDR yes 5
sunitinib KIT SSL via KIT yes 5
sunitinib PDGFRB SSL via PDGFRB yes 5
docetaxel, thalidomide MAPT SSL via MAPT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR SSL via KDR 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab MAPT SSL via MAPT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRB SSL via PDGFRB 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RAF1 SSL via RAF1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR SSL via KDR 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRB SSL via PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RAF1 SSL via RAF1 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR SSL via KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BCR SSL via BCR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.